Akebia Therapeutics has closed a $22 million series B round of investment that will take the company through a pair of phase 2b trials of its oral anemia drug, reports
MedCity News.
The funding is an important milestone for the Cincinnati-based pharmaceutical company as it pushes forward with development of AKB-6548, which is designed to promote levels of erythropoietin (EPO) for up to 12 hours in kidney disease patients. EPO is a hormone that promotes the growth of red blood cells in bone marrow.
Read the full story
here.